<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03464201</url>
  </required_header>
  <id_info>
    <org_study_id>GETHI 2016-01</org_study_id>
    <secondary_id>2015-004469-10</secondary_id>
    <nct_id>NCT03464201</nct_id>
  </id_info>
  <brief_title>Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study</brief_title>
  <acronym>GREKO III</acronym>
  <official_title>Open Label Phase II Clinical Trial of Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GreKo III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Tumores Huérfanos e Infrecuentes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Apices Soluciones S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Español de Tumores Huérfanos e Infrecuentes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The good tolerability profile of enzalutamide, the fact that the administration of steroids&#xD;
      is not necessary and the impressive results achieved in prostate cancer, make this drug an&#xD;
      ideal candidate to be tested in ovarian granulosa cancer, a tumor that could somehow be&#xD;
      considered as &quot;female prostate cancer&quot;.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 13, 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of responses according to RECIST 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Stabilization of disease plus the sum of partial and complete responses according to RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of progression of the disease according to RECIST 1.1 criteria or death of the patient for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of deaths for any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of Adverse Events per patient</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enzalutamide 160 mg daily p.o. (4 capsules 40mg per day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide 40 MG</intervention_name>
    <description>Enzalutamide 160 mg p.o. every day</description>
    <arm_group_label>Enzalutamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have given written informed consent&#xD;
&#xD;
          -  Women aged 18 years or over&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) ≤ 1&#xD;
&#xD;
          -  Diagnosis of histologically confirmed ovarian granulose carcinoma&#xD;
&#xD;
          -  Availability of sufficient biopsy material for confirmation of the diagnosis by a&#xD;
             centralized pathologist and determination of the mutation FOXL2402C→ G(C134W). If this&#xD;
             material is not available, principal investigator of the study will confirm&#xD;
             eligibility of the patient.&#xD;
&#xD;
          -  Metastatic or unresectable disease&#xD;
&#xD;
          -  Radiologically measurable disease. In case you there is not measurable disease,&#xD;
             principal investigator of the study will confirm eligibility of the patient. - - Life&#xD;
             expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Patients with adequate hepatic function, defined by: Aspartate transaminase (AST) and&#xD;
             alanine aminotransferase (ALT) serum values ≤ 3 x upper limit of normal (except in the&#xD;
             presence of metastasis in which case values ≤ 5 x upper limit of normal will be&#xD;
             allowed), Total bilirubin values ≤ 1,5 x upper limit of normal&#xD;
&#xD;
          -  Patients with adequate bone marrow function, defined by: Absolute neutrophil count ≥&#xD;
             1.5 x 109 / L, Platelets ≥100 x 109/L, Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Patients with adequate renal function: serum creatinine ≤ 1,5 x upper limit of normal&#xD;
&#xD;
          -  Absence of any disability to follow the study protocol&#xD;
&#xD;
          -  Women childbearing potential who are sexually active, not undergoing hysterectomy or&#xD;
             double adnexectomy, should follow the following contraceptive indications: Negative&#xD;
             Pregnancy Test in serum or urine in the 72 hours before the start of treatment, use of&#xD;
             a medically accepted method of contraception during: 2 months prior to the start of&#xD;
             study treatment, during the study and up to 3 months after the last dose of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with another primary tumor 2 years before beginning the drug under study,&#xD;
             with the exception of adequately treated or totally surgically removed cervical&#xD;
             carcinoma in-situ or basalioma or superficial bladder carcinoma&#xD;
&#xD;
          -  Patients who have received radical radiotherapy ≤ 4 weeks prior to the start of study&#xD;
             treatment or who have not recovered from toxicities of radiotherapy. Palliative&#xD;
             radiation therapy for painful bone lesions bone is allowed up to 14 days prior to the&#xD;
             beginning of the study treatment&#xD;
&#xD;
          -  History of seizures or any conditions that may predispose to suffer them&#xD;
&#xD;
          -  Current or previously treated brain metastases or disease leptomeningeal.&#xD;
&#xD;
          -  Patients with cardiac insufficiency or heart disease clinically significant including&#xD;
             any of the following: History or presence of uncontrolled severe ventricular&#xD;
             arrhythmias, clinically significant resting bradycardia, any of the following diseases&#xD;
             within 6 months prior to the start of the study drug -Myocardial infarction (MI),&#xD;
             severe or unstable angina, coronary revascularization, congestive cardiac&#xD;
             insufficiency (CCI), cerebrovascular accident (CVA), transient ischemic accident&#xD;
             (TIA)-&#xD;
&#xD;
          -  Patients with altered gastrointestinal function or with gastric disease that&#xD;
             significantly alters the absorption of enzalutamide, such as for example: severe ulcer&#xD;
             diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, extensive&#xD;
             resection (&gt; 1m) of the small bowel or inability to swallow oral medication. The&#xD;
             previous partial or total gastrectomy is not an exclusion criterion.&#xD;
&#xD;
          -  Diagnosis of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Women of childbearing potential not using an effective contraceptive method. -&#xD;
             Patients who do not want or can follow the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Due to kind of disease only female patients are acceptable for the trial</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Garcia-Donas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIOCC (Hospital Universitario HM Sanchinarro)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid Sanchinarro (CIOCC)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 19, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

